BIOLINERX     Print Page  Close Window

SEC filings
F-1
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document
 
F-1

 
 
BioLineRx Ltd.
(UNAUDITED)
 
               
Convenience translation
into USD
(Note 1b)
 
               
Three
   
Six
 
   
Three months ended
June 30,
   
Six months ended
June 30,
   
months ended
June 30,
 
   
2011
   
2012
   
2011
   
2012
   
2012
   
2012
 
   
NIS in thousands
   
In thousands
 
RESEARCH AND DEVELOPMENT EXPENSES, NET
    (10,405 )     (16,000 )     (16,789 )     (30,675 )     (4,079 )     (7,819 )
SALES AND MARKETING EXPENSES
    (1,323 )     (948 )     (2,073 )     (1,714 )     (242 )     (437 )
GENERAL AND ADMINISTRATIVE EXPENSES
    (3,348 )     (2,956 )     (6,274 )     (6,481 )     (754 )     (1,652 )
OPERATING LOSS
    (15,076 )     (19,904 )     (25,136 )     (38,870 )     (5,075 )     (9,908 )
NON-OPERATING INCOME, NET
    -       2,712       -       5,531       691       1,410  
FINANCIAL INCOME
    637       6,050       1,820       6,496       1,542       1,656  
FINANCIAL EXPENSES
    (1,965 )     (172 )     (4,732 )     (2,403 )     (44 )     (612 )
COMPREHENSIVE LOSS FOR THE PERIOD
    (16,404 )     (11,314 )     (28,048 )     (29,246 )     (2,886 )     (7,454 )
                                                 
   
NIS
     
USD
 
                                                 
LOSS PER ORDINARY SHARE - BASIC AND DILUTED
    (0.14 )     (0.06 )     (0.23 )     (0.18 )     (0.02 )     (0.04 )

The accompanying notes are an integral part of these condensed financial statements.